{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:06:45Z","timestamp":1791396405509,"version":"4.3.3"},"reference-count":23,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,12,18]]},"abstract":"<jats:p>Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however, a severe, long-lasting hypophosphataemia can lead to osteomalacia with associated bone pain. Lack of awareness of this complication results in delayed time to diagnosis and significant morbidity. We report a case of a patient with Crohn\u2019s disease and chronic iron-deficiency anaemia receiving multiple doses of FCM who developed severe hypophosphataemic osteomalacia with urinary phosphate loss and increased FGF23. FGF23 excess and osteomalacia resolved only months after FCM discontinuation and aggressive phosphate repletion. Potential mechanisms of FGF23 dysregulation are discussed, with the aim of raising awareness of this significant side effect for prescribers of chronic intravenous iron supplementation, and to help guide future studies to determine the safety of FCM in all patient populations.<\/jats:p>","DOI":"10.1136\/bcr-2017-222851","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T05:01:18Z","timestamp":1514955678000},"page":"bcr-2017-222851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":56,"title":["Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration"],"prefix":"10.1136","volume":"2018","author":[{"given":"Klara","family":"Klein","sequence":"first","affiliation":[{"name":"Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonda","family":"Asaad","sequence":"additional","affiliation":[{"name":"Southeastern Medical Oncology, Jacksonville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Econs","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Endocrinology, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969060-00007"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy","year":"2015","journal-title":"Int J Rheumatol"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous iron preparation determines hypophosphatemia risk","volume":"11","author":"Schaefer","year":"2016","journal-title":"PLoS One"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.4","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bone.2016.03.005","article-title":"Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women","volume":"86","author":"Imel","year":"2016","journal-title":"Bone"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-219160"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.8","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2008.008151"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2396"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.10","doi-asserted-by":"publisher","DOI":"10.1038\/81664"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bone.2016.10.015","article-title":"Genetic diseases resulting from disordered FGF23\/klotho biology","volume":"100","author":"Econs","year":"2017","journal-title":"Bone"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.497"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.101545198"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.14","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i1.50"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ijos.2015.1","article-title":"Fibroblast growth factor 23 and bone mineralisation","volume":"7","author":"Guo","year":"2015","journal-title":"Int J Oral Sci"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.196"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.17","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000447020.74593.6f"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1239"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.19","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2169\/naika.71.1566","article-title":"[2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide]","volume":"71","author":"Okada","year":"1982","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/apt.14043","article-title":"Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease","volume":"45","author":"Aksan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.005"},{"key":"2025082801285053000_2018.jan03_1.bcr-2017-222851.23","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2014.20"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-222851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:28:59Z","timestamp":1756369739000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-222851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":23,"alternative-id":["10.1136\/bcr-2017-222851"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-222851","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}